DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have received a consensus rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company.

DSRLF has been the subject of a number of research analyst reports. Zacks Research upgraded DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Finally, Piper Sandler assumed coverage on DiaSorin in a research note on Thursday. They issued a “neutral” rating on the stock.

DiaSorin Stock Performance

Shares of DSRLF stock opened at $84.10 on Monday. DiaSorin has a fifty-two week low of $66.50 and a fifty-two week high of $112.30. The business has a fifty day simple moving average of $71.24 and a 200-day simple moving average of $75.19.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.